BofA lowered the firm’s price target on GoodRx (GDRX) to $4.25 from $4.50 and keeps an Underperform rating on the shares after the company announced the resignation of CFO Karsten Voermann.

Citi analyst Daniel Grosslight lowered the firm’s price target on GoodRx (GDRX) to $6.25 from $7 and keeps a Buy rating on the shares as part of a 2025 outcook for the health technology and ...

largely driven by federal actions and voluntary price cuts from drugmakers, according to a Jan. 15 GoodRx report. GoodRx analyzed the price of 32 insulin products across all manufacturers and ...

GoodRx Holdings, Inc. engages in the business of a consumer-focused digital healthcare platform. The firm offers consumers free access to transparent and lower prices for brand and generic ...

GoodRx Holdings Inc. (NASDAQ:GDRX), a leading healthcare technology company specializing in prescription drug discounts and ...

Finally, Morgan Stanley decreased their target price on shares of GoodRx from $7.00 to $6.00 and set an “equal weight” rating for the company in a research report on Tuesday, December 17th.

Find the latest GoodRx Holdings, Inc. GDRX analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

GoodRx Holdings, Inc. (NASDAQ:GDRX – Get Free Report) dropped 8.4% during trading on Monday after Citigroup lowered their price target on the stock from $7.00 to $6.25. Citigroup currently has a ...